阿托伐他汀、阿仑膦酸钠联用对老年性骨质疏松的临床治疗效果、安全性分析

Clinical effect and safety analysis of atorvastatin combined with alendronate sodium in the treatment of senile osteoporosis

目的:探讨阿托伐他汀、阿仑膦酸钠联用对老年性骨质疏松的临床治疗效果、安全性。方法:收治老年性骨质疏松患者50例,随机分为两组。对照组给予阿仑膦酸钠治疗,试验组给予阿托伐他汀、阿仑膦酸钠联合治疗。比较两组临床治疗效果、VAS评分及不良反应发生情况。结果:试验组治疗有效率明显高于对照组,差异有统计学意义(P<0.05)。试验组不良反应发生率(20.0%)低于对照组(36.0%),差异有统计学意义(P<0.05)。治疗后试验组疼痛评分低于对照组,差异有统计学意义(P<0.05)。结论:老年性骨质疏松患者应用阿托伐他汀、阿仑膦酸钠联合治疗效果理想,不良反应发生率较低,能够显著降低VAS评分。

Objective:To investigate the clinical effect and safety of atorvastatin combined with alendronate sodium in the treatment of senile osteoporosis.Methods:50 cases of elderly patients with osteoporosis were divided into two groups randomly.The control group was treated with alendronate,while the experiment group was treated with atorvastatin combined with alendronate sodium.The clinical effect,VAS score and incidence of adverse reactions were compared between the two groups.Results:The effective rate of the experiment group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the experiment group was 20.0%,which was lower than that in the control group(36.0%),and the difference was statistically significant(P<0.05).After treatment,the pain score of the experiment group was lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusion:The clinical effect atorvastatin combined with alendronate sodium in the treatment of the elderly patients with osteoporosis was ideal,and the incidence of adverse reactions was lower,and the VAS score could be reduced significantly.